Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework
- PMID: 29300386
- PMCID: PMC6336098
- DOI: 10.1038/gim.2017.210
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework
Abstract
Purpose: We evaluated the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) variant pathogenicity guidelines for internal consistency and compatibility with Bayesian statistical reasoning.
Methods: The ACMG/AMP criteria were translated into a naive Bayesian classifier, assuming four levels of evidence and exponentially scaled odds of pathogenicity. We tested this framework with a range of prior probabilities and odds of pathogenicity.
Results: We modeled the ACMG/AMP guidelines using biologically plausible assumptions. Most ACMG/AMP combining criteria were compatible. One ACMG/AMP likely pathogenic combination was mathematically equivalent to pathogenic and one ACMG/AMP pathogenic combination was actually likely pathogenic. We modeled combinations that include evidence for and against pathogenicity, showing that our approach scored some combinations as pathogenic or likely pathogenic that ACMG/AMP would designate as variant of uncertain significance (VUS).
Conclusion: By transforming the ACMG/AMP guidelines into a Bayesian framework, we provide a mathematical foundation for what was a qualitative heuristic. Only 2 of the 18 existing ACMG/AMP evidence combinations were mathematically inconsistent with the overall framework. Mixed combinations of pathogenic and benign evidence could yield a likely pathogenic, likely benign, or VUS result. This quantitative framework validates the approach adopted by the ACMG/AMP, provides opportunities to further refine evidence categories and combining rules, and supports efforts to automate components of variant pathogenicity assessments.
Keywords: Bayesian framework; medical genetics; unclassified variants; variant classification; variants of uncertain significance.
Conflict of interest statement
SVT, MSG, and KMB: none, RLN receives salary and equity from Invitae Corp., serves as Chair of the Rare Disease Therapeutic Area Scientific Review Panel for Pfizer Corp., and is on the Advisory Board of Genome Medical. LGB is an uncompensated advisor for the Illumina Corp.
Figures

References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources